Subcutaneous immunoglobulin combined with recombinant human hyaluronidase to enable higher-volume SC infusion. Delivery-mechanism innovation on existing Ig therapy, not a new immunological target.
Dosing Notes
Investigational (Japan); SC infusion every 2, 3, or 4 weeks, up to 45 months in current trial.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Low ConfidenceBased on case reports, expert opinion, or early-phase data only
Phase 3 study of subcutaneous Ig delivery (vs standard IV) in Japanese CIDP/MMN patients; active, not recruiting.
Verified Jul 2026
Clinical Trial Registry
Phase 3 study of TAK-771 (subcutaneous Ig + rHuPH20) in Japanese CIDP/MMN patients — NCT05084053